40 Erie Street
Tel: (857) 285-6200
About Intellia Therapeutics
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Change life stories with genome editing therapies!
Stock Symbol: NTLA
Check out our Intellia office space!
172 articles with Intellia Therapeutics
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
Intellia Therapeutics, Inc. announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has approved a protocol amendment for the Company’s ongoing Phase 1 study of NTLA-2001 to include patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
Intellia Therapeutics, Inc. today announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition,
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021, and recent operational highlights.
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates
Intellia Therapeutics, Inc. will present its third quarter 2021 financial results and operational highlights in a conference call on November 4, 2021 at 8 a.m. ET.
The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Intellia Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis.
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced new data supporting novel capabilities of its CRISPR/Cas9 genome editing platform, which the Company plans to leverage for the development of future therapeutic candidates.
On Monday, LogicBio Therapeutics unveiled clinical trial results demonstrating the first-ever in vivo, nuclease-free genome editing in little humans.
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Intellia Therapeutics, Inc. (NASDAQ: NTLA), and SparingVision, today announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.
Genome-editing company Intellia Therapeutics and France-based SparingVision have partnered to develop new therapies for ocular diseases. The deal could be worth up to $600 million for Intellia.
Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of new data at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) meeting, taking place virtually from October 19-21, 2021.
10/11/2021Another busy week for clinical trial news. Here’s a look.
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
Intellia Therapeutics, Inc. today announced the authorization of its Clinical Trial Application (CTA) by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to initiate a Phase 1/2 study evaluating NTLA-2002 for the treatment of adults with hereditary angioedema (HAE).
EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.
Intellia Therapeutics, Inc. will present at Chardan’s 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 10:30 a.m. ET.
NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML).
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for NTLA-5001, the company’s first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer.
On June 26, Intellia announced the first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing in human patients.
Intellia Therapeutics, Inc. will present at the following virtual healthcare investor conferences in September: Thursday, September 9, 2021 Wells Fargo Healthcare Conference Time: 10:40 am ET
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported financial results for the second quarter ended June 30, 2021, and recent operational highlights.